We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.
- Authors
Wright, P F; Karron, R A; Belshe, R B; Thompson, J; Crowe, J E, Jr; Boyce, T G; Halburnt, L L; Reed, G W; Whitehead, S S; Anderson, E L; Wittek, A E; Casey, R; Eichelberger, M; Thumar, B; Randolph, V B; Udem, S A; Chanock, R M; Murphy, B R
- Abstract
A live-attenuated, intranasal respiratory syncytial virus (RSV) candidate vaccine, cpts-248/404, was tested in phase 1 trials in 114 children, including 37 1-2-month-old infants-a target age for RSV vaccines. The cpts-248/404 vaccine was infectious at 104 and 105 plaque-forming units in RSV-naive children and was broadly immunogenic in children >6 months old. Serum and nasal antibody responses in 1-2 month olds were restricted to IgA, had a dominant response to RSV G protein, and had no increase in neutralizing activity. Nevertheless, there was restricted virus shedding on challenge with a second vaccine dose and preliminary evidence for protection from symptomatic disease on natural reexposure. The cpts-248/404 vaccine candidate did not cause fever or lower respiratory tract illness. In the youngest infants, however, cpts-248/404 was unacceptable because of upper respiratory tract congestion associated with peak virus recovery. A live attenuated RSV vaccine for the youngest infant will use cpts-248/404 modified by additional attenuating mutations.
- Publication
The Journal of infectious diseases, 2000, Vol 182, Issue 5, p1331
- ISSN
0022-1899
- Publication type
Journal Article
- DOI
10.1086/315859